TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05140811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM01
Description: IMM01 is intravenously once a week, every 28 days for a treatment cycle;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM01
Description: IMM01 is intravenously once a week, every 28 days for a treatment cycle;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 75 mg/m/ day is administered subcutaneously for 7 consecutive days, with each 28-day treatment cycle planned for 6 treatment cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 75 mg/m/ day is administered subcutaneously for 7 consecutive days, with each 28-day treatment cycle planned for 6 treatment cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 75 mg/m/ day is administered subcutaneously for 7 consecutive days, with each 28-day treatment cycle planned for 6 treatment cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 75 mg/m/ day is administered subcutaneously for 7 consecutive days, with each 28-day treatment cycle planned for 6 treatment cycles
Study: NCT05828225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells injection
Description: CD19 CAR-T in the Treatment of Refractory Myasthenia Gravis
Study: NCT05287230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CoSHA (Coping with childhood Sexual Abuse, HIV, and Aging)
Description: Investigators will use concepts from the LIFT and REFLECT interventions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Participants will watch HIV and health related videos and discuss how it is related to aging with HIV.
Study: NCT06247670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-CPS-001
Description: CMP-CPS-001 consists of an antisense oligonucleotide solution that will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-CPS-001
Description: CMP-CPS-001 consists of an antisense oligonucleotide solution that will be administered subcutaneously.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is 0.9% normal saline solution and will be administered subcutaneously.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is 0.9% normal saline solution and will be administered subcutaneously.
Study: NCT04469699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stereotactic biopsy followed by stereotactical photodynamic therapy with 5-aminolevulinic acid
Description: 5-ALA HCl orally (20 mg/kg bw) 3,5-4,5 hours prior to induction of anaesthesia for stereotactic biopsy followed by stereotactical photodynamic therapy. All patients will receive further treatment of recurrent glioblastoma at the investigator´s discretion (best possible care).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stereotactic biopsy
Description: Stereotactic biopsy. All patients will receive further treatment of recurrent glioblastoma at the investigator´s discretion (best possible care).
Study: NCT05706987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: continuous lidocaine infusion perioperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: normal saline
Study: NCT04982627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BNI Chatbot
Description: The BNI Chatbot is a web application that guides participants through a brief motivational intervention that motivates them to engage in treatment for opioid use disorder.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OUD Education & Treatment Resources
Description: The OUD Education \& Treatment Resources intervention is a web application that provides OUD education and treatment resources.
Study: NCT04938713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 50 MG/ML
Description: Intravenous Ketalar® 0,30 mg/kg in 1 hour.

Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine 50 MG/ML
Description: Intravenous Ketalar® 0,30 mg/kg in 1 hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine 25 MG/ML
Description: Intravenous Vesierra® 0,15mg/kg in 1 hour.

Intervention type: DRUG
Group type: OTHER
Intervention: Esketamine 25 MG/ML
Description: Intravenous Vesierra® 0,15mg/kg in 1 hour.
Study: NCT05469022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant lazertinib
Description: Lazertinib 240mg p.o once daily.
Study: NCT06080165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Experimental: Sirolimus Participants that are 5 to 12.99 years old will start at 1 mg/m2/dose. Participants that are 13 to 45.99 years old and \< 39.99 kg in weight will also start on 1 mg/day. Participants that are 13 to 45.99 years old and \> 40 kg in weight will start on 2 mg/day. The target blood level will be 5-15 ng/ml with dose adjustment based on clinical labs of sirolimus levels. The target blood level will be 5-15 ng/ml with dose adjustment based on sirolimus levels obtained every 2 to 3 weeks after every dose change.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT05956522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Empagliflozin And Linagliptin Tablets
Description: specification: 25 mg/5 mg, manufacturer: Qilu Pharmaceutical (Hainan) Co., Ltd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Empagliflozin And Linagliptin Tablets
Description: specification: 25 mg/5 mg, manufacturer: Qilu Pharmaceutical (Hainan) Co., Ltd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Empagliflozin And Linagliptin tablets
Description: specification: 25 mg/5 mg, manufacturer: Boehringer Ingelheim International GmbH \& Co. KG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Empagliflozin And Linagliptin tablets
Description: specification: 25 mg/5 mg, manufacturer: Boehringer Ingelheim International GmbH \& Co. KG
Study: NCT04736732

Intervention type: OTHER
Intervention: Medical follow-up
Description: Patients will be followed for medical evaluation and for biobanking of data and biological samples.

Intervention type: OTHER
Intervention: Medical follow-up
Description: Patients will be followed for medical evaluation and for biobanking of data and biological samples.
Study: NCT06371066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental group
Description: the experimental group was educated by video

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: the control group was educated by traditional formal training
Study: NCT05584085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-DE
Description: Acceptance and Commitment Therapy is a third-wave psychological therapy to cultivate participants' acceptance attitude to diabetes and motivate them for a value-driven persistent diabetes self-management, directed by six psychological processes in the ACT hexagonal model, including acceptance, cognitive defusion, the present moment, self-as-context, value clarification and committed action.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: ACT-DE
Description: Acceptance and Commitment Therapy is a third-wave psychological therapy to cultivate participants' acceptance attitude to diabetes and motivate them for a value-driven persistent diabetes self-management, directed by six psychological processes in the ACT hexagonal model, including acceptance, cognitive defusion, the present moment, self-as-context, value clarification and committed action.
Study: NCT06476431

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dual task
Description: The intervention program will be a program created by the researcher based on the iPad application Brainilis The tasks (logic, memory, math, and concentration) will be performed using a Type-C cable connected to the smartglasses, and the difficulty level will be adjusted according to the individual's cognitive ability. The experimental group will perform cognitive tasks with the smartglasses while simultaneously performing a walking task on a treadmill. This will be done three times a week for 30 minutes for four weeks. The subjects will not be able to touch the answers, so they will tell the therapist what they think is the correct answer and the therapist will touch the iPad to move on to the next step. The investigators will start with 10 minutes on the treadmill without incline, followed by a 5 minute break, then 10 minutes on the treadmill with incline, followed by a 5 minute break. It will run for 30 minutes, 3 times a week for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non dual task
Description: No cognitive task, just treadmill walking. Same as the experimental group 1: 10 minutes without treadmill incline, followed by a 5 minute rest period, followed by 10 minutes on the treadmill with incline, followed by a 5 minute rest period. It will run for 30 minutes, 3 times a week for 4 weeks.
Study: NCT05691621

Intervention type: DRUG
Intervention: Standard Reagents, Whole Blood
Description: All patients receive standard treatment, only their blood and urine samples are needed

Intervention type: DRUG
Intervention: Standard Reagents, Whole Blood
Description: All patients receive standard treatment, only their blood and urine samples are needed

Intervention type: DRUG
Intervention: Standard Reagents, Whole Blood
Description: All patients receive standard treatment, only their blood and urine samples are needed
Study: NCT04759456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remotely-supervised rehabilitation program
Description: Include nutrition, health-related lifestyle and behavioral changes recommendations, and at least 5 times a week 30 minutes of moderate-intensity aerobic training, 10 minutes of inspiratory and expiratory muscle training with breathing device and 10 minutes of oropharyngeal exercise along with individually titrated CPAP therapy
Study: NCT06306768

Intervention type: DEVICE
Group type: OTHER
Intervention: Activity Monitoring
Description: Tracking participants step activity, workout frequency, minutes in target heart rate zone, and type of exercises completed over 1 year period. Goals will be set and customized by a research physical therapist to participants based on best practice recommendations.
Study: NCT04833400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICRS
Description: Patients undergo 30-minute aerobic training with ICRS, 3 sessions a week, for 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAET
Description: Patients undergo 30-minute aerobic training with TAET, 3 sessions a week, for 4 weeks.
Study: NCT06093971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam
Description: Remimazolam is administered for anesthesia induction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is administered for anesthesia induction.
Study: NCT05398705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cepharanthine
Description: Low-dose: Day 1\~5: 20mg, Q8H X 5 days (60mg/day)+SMT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 1\~5: placebo+SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor, antiviral drug and Chinese medicine treatment, etc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cepharanthine
Description: High-dose: Day 1\~5: 40mg, Q8H X 5 days (120mg/day) +SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor and Chinese traditional medicine, etc.
Study: NCT05808816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus Crispatus M247
Description: Oral supplementation of Lactobacillus Crispatus M247 in patients with cervical low grade lesions HPV related
Study: NCT05856578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mulberry Twig Alkaloid Tablet
Description: Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet 50mg po tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canagliflozin
Description: Canagliflozin 100mg po qd
Study: NCT05278013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dermabond
Description: High viscosity Dermabond is a sterile, liquid topical skin adhesive containing monomeric (2-OCA) formulation and the colorant D \& C Violet # 2. The product has a syrup-like in viscosity and polymerizes within minutes when applied to the skin. 2-OCA is an effective barrier against microbial penetration by Gram-positive (inc. methicillin-resistant Staphylococcus aureus) and Gram-negative motile and nonmotile species as long the as the film is intact (11-13). The high viscosity of Dermabond is intended to reduce the risk of unintended placement of the adhesive during the application process to other body parts, patient's clothing or in between the skin layers in the wound, which can result in delayed wound healing.
Study: NCT04761159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Different mixture of ketamin-propofol will apply for anesthesia induction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Different mixture of ketamin-propofol will apply for anesthesia induction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Different mixture of ketamin-propofol will apply for anesthesia induction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Different mixture of ketamin-propofol will apply for anesthesia induction.
Study: NCT05184621

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eyesing Redlight Instrument
Description: Eyesing Instrument developed by Suzhou Industrial Park Zoguan Medical Equipment Co. and conventional optometry.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eyesing Redlight Instrument
Description: Eyesing Instrument developed by Suzhou Industrial Park Zoguan Medical Equipment Co. and conventional optometry.
Study: NCT06307509

Intervention type: OTHER
Intervention: Diagnosis of sepsis
Description: Patients will be recruited on the basis of a diagnosis of sepsis, as this is the exposure of interest
Study: NCT05181397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants in tocilizumab group will receive intravenous 8mg/kg tocilizumab.
Study: NCT05721573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC008
Description: Given by subcutaneous injection
Study: NCT03722693

Intervention type: DEVICE
Intervention: Functional electrical stimulation based treatment
Description: Two types of multi-pad electrodes will be used during this study. Both were designed for covering the extrinsic muscles of the hand. Electrodes are comprised of 8 pads that act as anodes and 32 pads that acted as cathodes. The shape and distribution of the conductive pads within the electrodes were designed considering the motor points for achieving different movement primitives (wrist extension, wrist flexion, fingers extension, fingers flexion, index extension, index flexion, thumb extension, and thumb flexion). Each participant will receive 5 assessment sessions:1. before starting the interventions, 2. after the 7 days of standard care, 3. after 7 days of first FES based protocol, 4.after another 7 days of standard care and 5. after seven days of the other FES based intervention
Study: NCT06315101

Intervention type: DRUG
Intervention: Chinese Herbal Medicine
Description: Patients were treated with Chinese herbal medicine (CHM). CHM refers to the administration of a syndrome-specific herbal formula prescribed by a Traditional Chinese Medicine (TCM) physician after an uHCC diagnosis. Physicians determine the formula based on tongue and pulse examinations and personalized TCM syndromes derived from individual patient symptoms, adhering to established therapeutic principles and long-term clinical experience of physicians. The CHM formula applied in the study followed overarching TCM strategies, including reinforcing spleen qi, harmonizing liver qi, addressing blood stasis, and detoxification.
Study: NCT05744583

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Packed red cell transfusion
Description: Type O RhD negative packed red cell transfusion during prehospital emergency care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole blood transfusion
Description: Type O RhD positive, low titer whole blood transfusion during prehospital emergency care
Study: NCT05848323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-week Relaxation Training
Description: A 4-session telehealth Relaxation Training intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis and the cognitive behavioral model of multiple sclerosis fatigue, b) treatment rationale, b) didactic and experiential training in relaxation techniques such as diaphragmatic breathing, progressive muscle relaxation, autogenic relaxation, and guided imagery, and c) goal setting and problem-solving barriers focused on integrating relaxation practices into daily routine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-week Behavioral Activation
Description: A 4-session telehealth Behavioral Activation intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis, the cognitive behavioral model of multiple sclerosis fatigue, and self-monitoring activity and energy, b) treatment rationale, c) identification of values/priorities to guide activities, d) activity planning, e) goal setting and problem-solving barriers to engaging in activities.
Study: NCT05721573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC008
Description: Given by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABC008
Description: Given by subcutaneous injection
Study: NCT06320522

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketone Monoester
Description: Commercial dietary supplement intended raise blood ketone body levels

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketone Monoester
Description: Commercial dietary supplement intended raise blood ketone body levels

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drink (2mM sucrose octaacetate) taste and volume matched to the ketone monoester drinks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drink (2mM sucrose octaacetate) taste and volume matched to the ketone monoester drinks
Study: NCT05797883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX/FOLFIRI
Description: mFOLFOX6 ：oxaliplatin 85mg/m² IV infusion 2h d1, 5-FU 400mg/m² push d1, Then 5-FU 1200mg/(m2▪d)×2d+Levofolinic Acid 200mg/m² continuous mixed infusion for 46-48h (total 5-FU 2400mg/m²); FOLFIRI ：Irinotecan 180mg/m ² static pulse infusion 30min\~90min d1, 5-FU 400mg/m² push d1, Then 5-FU 1200mg/(m2▪d)×2d+ Levofolinic Acid 200mg/m² continuous mixed infusion for 46-48h (total 5-FU 2400mg/m²); The combination of cetuximab/bevacizumab and other targeted agents depends on the patient.
Study: NCT05134714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/CAM zircon band and loop space maintainer
Description: Solid monolithic zirconia material which utilizes CAD/CAM technology for its designing and milling of the restoration will be used for fabrication of the space maintainer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAD/CAM zircon band and loop space maintainer
Description: Solid monolithic zirconia material which utilizes CAD/CAM technology for its designing and milling of the restoration will be used for fabrication of the space maintainer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional metal band and loop space maintainer
Description: Stainless steel appropriate band will be selected according to the size of the abutment teeth and then design of the loop will be obtained, then will be send to the laboratory for soldering.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional metal band and loop space maintainer
Description: Stainless steel appropriate band will be selected according to the size of the abutment teeth and then design of the loop will be obtained, then will be send to the laboratory for soldering.
Study: NCT06313996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liso-cel
Description: Specified dose on specified days
Study: NCT05266898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human papillomavirus 9-valent vaccine, recombinant
Description: Subunit vaccine against 9 genotypes of human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52, 58)